EGFR and central nervous system cancer: In addition, MAPT can alter the characteristics of the glioma mesenchyme by inhibiting EGFR-mediated NF- κB and TAZ signaling pathways, inhibit the transformation of tumor cells into pericytes, normalize tumor blood vessels, and reduce the invasiveness of gliomas (Gargini et al., 2020).